Cresco Labs (CRLBF) EBIT (2020 - 2026)

Cresco Labs has reported EBIT for 7 years, with the latest figure at $11.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 17.78% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at -$30.4 million (down 133.15% YoY), and the FY2025 full-year result was -$28.0 million, down 126.08% from the prior year.
• EBIT for Q1 2026 stood at $11.2 million, up from -$75.5 million in the prior quarter.
• The five-year high for EBIT was $32.4 million in Q2 2024, with the low at -$143.5 million in Q4 2022.
• Historically, EBIT has averaged -$4.8 million across 5 years, with a median of $16.2 million in 2022.
• Annual changes were most pronounced in 2022 — EBIT sank 1022.28% — and 2024, when it surged 713.25%.
• Cresco Labs' EBIT stood at -$143.5 million in 2022, then surged by 118.89% to $27.1 million in 2023, then slipped by 28.39% to $19.4 million in 2024, then sank by 489.29% to -$75.5 million in 2025, then surged by 114.79% to $11.2 million in 2026.
• The last three EBIT figures came in at $11.2 million (Q1 2026), -$75.5 million (Q4 2025), and $17.8 million (Q3 2025), per Business Quant data.